Pharmaceutical co-crystal compositions and related methods of use
View Patent ↗The present invention comprises pharmaceutical compositions comprising a co-crystal of an API and a co-crystal former, and methods of making and using the same.
1. A pharmaceutical co-crystal comprising:
a) a stavudine:melamine co-crystal, wherein said stavudine:melamine co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks at 11.06, 22.40, and 24.64 degrees 2-theta;
b) a stavudine:melamine co-crystal, wherein said stavudine:melamine co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks at 11.06, 18.32, and 20.24 degrees 2-theta;
c) a stavudine:melamine co-crystal, wherein said stavudine:melamine co-crystal is characterized by a powder X-ray diffraction pattern that is substantially as shown in FIG. 18 ;
d) a stavudine:melamine co-crystal, wherein said stavudine:melarnine co-crystal is characterized by an IR spectrum comprising peaks at 1655, 1446, and 799 cm −1 ;
e) a stavudine:melamine co-crystal, wherein said stavudine:melamine co-crystal is characterized by an IR spectrum comprising peaks at 1542, 1268, and 1091 cm −1 ;
f) a stavudine :2-aminopyridine co-crystal, wherein said stavudine:2-aminopyridine co-crystal is characterized by an IR spectrum comprising peaks at 1698, 1433, and 1075 cm −1 ;
g) a stavudine:2-aminopyridine co-crystal, wherein said stavudine:2-aminopyridine co-crystal is characterized by an IR spectrum comprising peaks at 1666, 1221, and 974 cm −1 ;
h) a stavudine:2-aminopyridine co-crystal, wherein said stavudine:2-aminopyridine co-crystal is characterized by an IR spectrum comprising peaks at 1698, 1666, and 1629 cm −1 ; or
i) a stavudine:2-aminopyridine co-crystal, wherein said stavudine:2-aminopyridine co-crystal is characterized by IR spectrum that is substantially as shown in FIG. 20A .
2. The pharmaceutical co-crystal according to claim 1 , wherein said co-crystal is a stavudine:melamine co-crystal characterized by a powder X-ray diffraction pattern comprising peaks at 11.06, 22.40, and 24.64 degrees 2-theta.
3. The pharmaceutical co-crystal according to claim 1 , wherein said co-crystal is a stavudine:melamine co-crystal characterized by a powder X-ray diffraction pattern comprising peaks at 11.06, 18.32, and 20.24 degrees 2-theta.
4. The pharmaceutical co-crystal according to claim 1 , wherein said co-crystal is a stavudine:melamine co-crystal characterized by a powder X-ray diffraction pattern that is substantially as shown in FIG. 18 .
5. The pharmaceutical co-crystal according to claim 1 , wherein said co-crystal is a stavudine:melamine co-crystal characterized by an IR spectrum comprising peaks at 1655, 1446, and 799 cm −1 .
6. The pharmaceutical co-crystal according to claim 1 , wherein said co-crystal is a stavudine:melamine co-crystal characterized by an IR spectrum comprising peaks at 1542, 1268, and 1091 cm −1 .
7. The pharmaceutical co-crystal according to claim 1 , wherein said co-crystal is a stavudine:2-aminopyridine co-crystal characterized by an IR spectrum comprising peaks at 1698, 1433, and 1075 cm −1 .
8. The pharmaceutical co-crystal according to claim 1 , wherein said co-crystal is a stavudine:2-aminopyridine co-crystal characterized by an IR spectrum comprising peaks at 1666, 1221, and 974 cm −1 .
9. The pharmaceutical co-crystal according to claim 1 , wherein said co-crystal is a stavudine:2-aminopyridine co-crystal characterized by an IR spectrum comprising peaks at 1698, 1666, and 1629 cm −1 .
10. The pharmaceutical co-crystal according to claim 1 , wherein said co-crystal is a stavudine:2-aminopyridine co-crystal characterized by IR spectrum that is substantially as shown in FIG. 20A .
11. The stavudine:melamine co-crystal according to claim 1 , wherein said stavudine:melamine co-crystal has a melting point at about 186-190 degrees C.
12. The stavudine:melamine co-crystal according to claim 1 , wherein said stavudine:melamine co-crystal is characterized by a DSC thermogram comprising an endothermic transition at about 212 degrees C.
13. The stavudine:2-aminopyridine co-crystal according to claim 1 , wherein said stavudine:2-aminopyridine co-crystal has a melting point at about 120-122 degrees C.
14. The stavudine:2-aminopyridine co-crystal according to claim 1 , wherein said stavudine:2-aminopyridine co-crystal is characterized by a DSC thermogram comprising an endothermic transition at about 156 degrees C.
15. A pharmaceutical composition comprising a pharmaceutical co-crystal of claim 1 .